How Seasons Affect Kidney Health in Post-Menopausal Females

September 30, 2025 updated by: Joseph Watso, Florida State University

Seasonal Changes in Kidney Function Among Female Adults Post-Menopause

The investigators are assessing how seasonal changes affect kidney function biomarkers in post-menopausal women, an understudied group. While heat stress can reduce kidney function, previous research has not accounted for physical activity, diet, hydration, or sun exposure.

Study Overview

Status

Completed

Conditions

Detailed Description

Intense heat stress on the body can reduce kidney function. A recent study reported that blood markers of kidney function are lower among people in hotter climates. However, these data did not consider physical activity, food intake, fluid intake, time spent outdoors, or exposure to sunlight. Therefore, the investigators invite participants to help determine whether there are seasonal changes in kidney function biomarkers. This will also help the investigators understand if physical activity, food intake, fluid intake, time spent outdoors, or exposure to sunlight affect kidney function biomarkers between seasons. The investigators are studying female adults post-menopause since they are an understudied group.

Study Type

Observational

Enrollment (Actual)

18

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Tallahassee, Florida, United States, 32306
        • Florida State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants will be recruited from the greater Tallahassee, Florida area.

Description

Inclusion Criteria:

  • Female aged ≥55 years old
  • Self Reported as at least one year post-menopause
  • Live in Tallahassee, Florida, or the surrounding area

Exclusion Criteria:

  • Have a BMI of ≥30 kg/m2
  • Systolic blood pressure of ≥140 and/or diastolic blood pressure ≥90 mmHg
  • Self Reported Current or recent (regular use within the past six months) use of a diuretic medication
  • Self Reported: Uncontrolled cardiovascular, respiratory, neurological, renal, liver, or metabolic health condition
  • Current or recent (regular use within the past six months) use of tobacco, nicotine, nonsteroidal anti-inflammatory products
  • No regular (≥once per week) purposeful heat exposure (e.g., sauna, spa, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Winter
Assessment of the cohort in winter 2025 (visit 1).
This research focuses on examining seasonal variations in kidney function among postmenopausal females. As an observational study, our approach is non-interventional.
Summer
Assessment of the cohort in summer 2025 (visit 2).
This research focuses on examining seasonal variations in kidney function among postmenopausal females. As an observational study, our approach is non-interventional.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma neutrophil gelatinase-associated lipocalin (NGAL)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
Changes in NGAL will be measured in blood samples using enzyme-linked immunosorbent assay.
Visit 1 (0 months) and Visit 2 (7 months)
Urinary neutrophil gelatinase-associated lipocalin (NGAL)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
Changes in NGAL will be measured in urine samples using radioimmunoassay.
Visit 1 (0 months) and Visit 2 (7 months)
Insulin-like growth factor-binding protein 7 (IGFBP7)*Tissue inhibitor of metalloproteinase-2 (TIMP-2)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
The product of Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase-2 (TIMP-2) will be measured in blood samples using enzyme-linked immunosorbent assays.
Visit 1 (0 months) and Visit 2 (7 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
estimated glomerular filtration rate (eGFR)
Time Frame: Visit 1 (0 months) and Visit 2 (7 months)
eGFR will be calculated from creatinine using CKD-EPI equation.
Visit 1 (0 months) and Visit 2 (7 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joseph Watso, PhD, Florida State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2025

Primary Completion (Actual)

September 3, 2025

Study Completion (Actual)

September 3, 2025

Study Registration Dates

First Submitted

February 14, 2025

First Submitted That Met QC Criteria

March 4, 2025

First Posted (Actual)

March 10, 2025

Study Record Updates

Last Update Posted (Estimated)

October 6, 2025

Last Update Submitted That Met QC Criteria

September 30, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00005199

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data with all HIPAA identifiers removed may be shared in future collaborative efforts pending appropriate data and/or material transfer agreement approvals.

IPD Sharing Time Frame

One year after completion of the trial, indefinitely

IPD Sharing Access Criteria

A formal plan identifying the intended use of the data and proper completion of appropriate data and/or material transfer agreement approvals with the study PI and their institution.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Female

Clinical Trials on There will be no intervention.

Subscribe